RT Journal Article
SR Electronic
T1 Clinical Features of COVID-19 on Patients With Neuromyelitis Optica Spectrum Disorders
JF Neurology - Neuroimmunology Neuroinflammation
JO Neurol Neuroimmunol Neuroinflamm
FD Lippincott Williams & Wilkins
SP e1060
DO 10.1212/NXI.0000000000001060
VO 8
IS 6
A1 Samira Luisa Apostolos-Pereira
A1 Lis Campos Ferreira
A1 Mateus Boaventura
A1 Nise Alessandra de Carvalho Sousa
A1 Gabriela Joca Martins
A1 José Arthur d'Almeida
A1 Milena Pitombeira
A1 Lucas Silvestre Mendes
A1 Thiago Fukuda
A1 Hideraldo Luíz Souza Cabeça
A1 Luciano Chaves Rocha
A1 Bianca Santos de Oliveira
A1 Carla Renata Vieira Stella
A1 Enedina Maria Lobato de Oliveira
A1 Leizian de Souza Amorim
A1 Andréa Ferrari de Castro
A1 Antonio Pereira Gomes Neto
A1 Guilherme Diogo Silva
A1 Lucas Bueno
A1 Maria de Morais Machado
A1 Rafael Castello Dias-Carneiro
A1 Ronaldo Maciel Dias
A1 Alvaro Porto Moreira
A1 Ana Piccolo
A1 Anderson Kuntz Grzesiuk
A1 Andre Muniz
A1 Caio Diniz Disserol
A1 Claudia Ferreira Vasconcelos
A1 Damacio Kaimen-Maciel
A1 Denise Sisterolli Diniz
A1 Elizabeth Comini-Frota
A1 Fernando Coronetti Rocha
A1 Gutemberg Augusto Cruz dos Santos
A1 Yara Dadalti Fragoso
A1 Guilherme Sciascia do Olival
A1 Heloisa Helena Ruocco
A1 Heloise Helena Siqueira
A1 Henry Koity Sato
A1 José Alexandre Figueiredo, Jr
A1 Leandro Cortoni Calia
A1 Mario Emilio Teixeira Dourado, Jr
A1 Letícia Scolari
A1 Herval Ribeiro Soares Neto
A1 Luiz Melges
A1 Marcus Vinicius Magno Gonçalves
A1 Maria Lucia Vellutini Pimentel
A1 Marlise de Castro Ribeiro
A1 Omar Gurrola Arambula
A1 Paulo Diniz da Gama
A1 Renata Leite Menon
A1 Rodrigo Barbosa Thomaz
A1 Rogério de Rizo Morales
A1 Silvana Sobreira
A1 Suzana Nunes Machado
A1 Taysa Gonsalves Jubé Ribeiro
A1 Valéria Coelho Santa Rita Pereira
A1 Vanessa Maia Costa
A1 Adaucto Wanderley da Nóbrega Junior
A1 Soniza Vieira Alves-Leon
A1 Marilia Mamprim de Morais Perin
A1 Eduardo Donadi
A1 Tarso Adoni
A1 Sidney Gomes
A1 Maria Brito Ferreira
A1 Dagoberto Callegaro
A1 Maria Fernanda Mendes
A1 Doralina Brum
A1 Felipe von Glehn
A1 ,
YR 2021
UL http://nn.neurology.org/content/8/6/e1060.abstract
AB Background and Objectives To describe the clinical features and disease outcomes of coronavirus disease 2019 (COVID-19) in patients with neuromyelitis optica spectrum disorder (NMOSD).Methods The Neuroimmunology Brazilian Study Group has set up the report of severe acute respiratory syndrome (SARS-CoV2) cases in patients with NMOSD (pwNMOSD) using a designed web-based case report form. All neuroimmunology outpatient centers and individual neurologists were invited to register their patients across the country. Data collected between March 19 and July 25, 2020, were uploaded at the REDONE.br platform. Inclusion criteria were as follows: (1) NMOSD diagnosis according to the 2015 International Panel Criteria and (2) confirmed SARS-CoV2 infection (reverse transcription-polymerase chain reaction or serology) or clinical suspicion of COVID-19, diagnosed according to Center for Disease Control / Council of State and Territorial Epidemiologists (CDC/CSTE) case definition. Demographic and NMOSD-related clinical data, comorbidities, disease-modifying therapy (DMT), COVID-19 clinical features, and severity were described.Results Among the 2,061 pwNMOSD followed up by Brazilian neurologists involved on the registry of COVID-19 in pwNMOSD at the REDONE.br platform, 34 patients (29 women) aged 37 years (range 8–77), with disease onset at 31 years (range 4–69) and disease duration of 6 years (range 0.2–20.5), developed COVID-19 (18 confirmed and 16 probable cases). Most patients exhibited mild disease, being treated at home (77%); 4 patients required admission at intensive care units (severe cases); and 1 patient died. Five of 34 (15%) presented neurologic manifestations (relapse or pseudoexacerbation) during or after SARS-CoV2 infection.Discussion Most NMOSD patients with COVID-19 presented mild disease forms. However, pwNMOSD had much higher odds of hospitalization and intensive care unit admission comparing with the general Brazilian population. The frequency of death was not clearly different. NMOSD disability, DMT type, and comorbidities were not associated with COVID-19 outcome. SARS-CoV2 infection was demonstrated as a risk factor for NMOSD relapses. Collaborative studies using shared NMOSD data are needed to suitably define factors related to COVID-19 severity and neurologic manifestations.AQP4=aquaporin 4; CBA=cell-based assay; CI=confidence interval; COVID-19=coronavirus disease 2019; DMT=disease-modifying therapy; MS=multiple sclerosis; NMOSD=neuromyelitis optica spectrum disorders; OR=odds ratio; pwNMOSD=patients with NMOSD; RT-PCR=reverse transcription-polymerase chain reaction; SARS=severe acute respiratory syndrome